AWARE Ceftaroline Surveillance Program (2008–2010): Trends in Resistance Patterns Among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States

ABSTRACTDelafloxacin, an investigational anionic fluoroquinolone, is active against a broad range of Gram-positive and Gram-negative bacteria. In this study, 200Streptococcus pneumoniae(plus 30 levofloxacin-resistant isolates), 200Haemophilus influenzae, and 100Moraxella catarrhalisisolates selected primarily from the United States (2014) were tested against delafloxacin and comparator agents. Delafloxacin was the most potent agent tested. MIC50and MIC90values against allS. pneumoniaeisolates were 0.008 and 0.015 μg/ml. Delafloxacin susceptibility was not affected by β-lactamase status againstH. influenzaeandM. catarrhalis.

Download Full-text

Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996–1997 respiratory season

Diagnostic Microbiology and Infectious Disease ◽

10.1016/s0732-8893(97)00195-8 ◽

1997 ◽

Vol 29 (4) ◽

pp. 249-257 ◽

Cited By ~ 195

Author(s):

Clyde Thornsberry ◽

Penny Ogilvie ◽

James Kahn ◽

Yolanda Mauriz

Keyword(s):

United States ◽

Streptococcus Pneumoniae ◽

Antimicrobial Resistance ◽

Haemophilus Influenzae ◽

Moraxella Catarrhalis ◽

The United States

Download Full-text

Activity of BMS284756 against 2,681 recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis: report from The SENTRY Antimicrobial Surveillance Program (2000) in Europe, Canada and the United States

Diagnostic Microbiology and Infectious Disease ◽

10.1016/s0732-8893(01)00224-3 ◽

2001 ◽

Vol 39 (4) ◽

pp. 245-250 ◽

Cited By ~ 19

Author(s):

Douglas J. Biedenbach ◽

Ronald N. Jones ◽

Michael A. Pfaller

Keyword(s):

United States ◽

Haemophilus Influenzae ◽

Moraxella Catarrhalis ◽

The United States ◽

Clinical Isolates ◽

Surveillance Program ◽

Antimicrobial Surveillance

Download Full-text

Haemophilus influenzae and Moraxella catarrhalis from Patients with Community-Acquired Respiratory Tract Infections: Antimicrobial Susceptibility Patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997)

Antimicrobial Agents and Chemotherapy ◽

10.1128/aac.43.2.385 ◽

1999 ◽

Vol 43 (2) ◽

pp. 385-389 ◽

Cited By ~ 125

Author(s):

Gary V. Doern ◽

Ronald N. Jones ◽

Michael A. Pfaller ◽

Kari Kugler ◽

Keyword(s):

United States ◽

Respiratory Tract ◽

Haemophilus Influenzae ◽

Moraxella Catarrhalis ◽

Antimicrobial Agents ◽

The United States ◽

Surveillance Program ◽

Antimicrobial Surveillance ◽

Tract Infections ◽

Resistance Rates

Between February and June of 1997, a large number of community-acquired respiratory tract isolates of Haemophilus influenzae (n = 1,077) and Moraxella catarrhalis (n = 503) from 27 U.S. and 7 Canadian medical centers were characterized as part of the SENTRY Antimicrobial Surveillance Program. Overall prevalences of β-lactamase production were 33.5% in H. influenzae and 92.2% in M. catarrhalis with no differences noted between isolates recovered in the United States and those from Canada. Among a total of 21 different antimicrobial agents tested, including six cephalosporins, a β-lactamase inhibitor combination, three macrolides, tetracycline, trimethoprim-sulfamethoxazole (TMP-SMX), rifampin, chloramphenicol, five fluoroquinolones, and quinupristin-dalfopristin, resistance rates of >5% with H. influenzae were observed only with cefaclor (12.8%) and TMP-SMX (16.2%).

Download Full-text

Comparative in vitro activity of gemifloxacin to other fluoroquinolones and non-quinolone agents against Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in the United States in 1999–2000

International Journal of Antimicrobial Agents ◽

10.1016/s0924-8579(01)00431-9 ◽

2002 ◽

Vol 19 (1) ◽

pp. 33-37 ◽

Cited By ~ 13

Author(s):

Laura M Koeth ◽

Michael R Jacobs ◽

Saralee Bajaksouzian ◽

Anne Zilles ◽

Gengrong Lin ◽

...

Keyword(s):

United States ◽

Streptococcus Pneumoniae ◽

Haemophilus Influenzae ◽

Moraxella Catarrhalis ◽

The United States ◽

Vitro Activity ◽

In Vitro Activity

Download Full-text

Need for Annual Surveillance of Antimicrobial Resistance in Streptococcus pneumoniae in the United States: 2-Year Longitudinal Analysis

Antimicrobial Agents and Chemotherapy ◽

10.1128/aac.45.4.1037-1042.2001 ◽

2001 ◽

Vol 45 (4) ◽

pp. 1037-1042 ◽

Cited By ~ 94

Author(s):

Daniel F. Sahm ◽

James A. Karlowsky ◽

Laurie J. Kelly ◽

Ian A. Critchley ◽

Mark E. Jones ◽

...

Keyword(s):

United States ◽

Streptococcus Pneumoniae ◽

Antimicrobial Resistance ◽

Antimicrobial Agents ◽

The United States ◽

Multidrug Resistant ◽

Fluoroquinolone Resistance ◽

Resistance Patterns ◽

Changing Patterns ◽

Resistance To Penicillin

ABSTRACT Although changing patterns in antimicrobial resistance inStreptococcus pneumoniae have prompted several surveillance initiatives in recent years, the frequency with which these studies are needed has not been addressed. To approach this issue, the extent to which resistance patterns change over a 1-year period was examined. In this study we analyzed S. pneumoniaeantimicrobial susceptibility results produced in our laboratory with isolates obtained over 2 consecutive years (1997–1998 and 1998–1999) from the same 96 institutions distributed throughout the United States. Comparison of results revealed increases in resistant percentages for all antimicrobial agents studied except vancomycin. For four of the agents tested (penicillin, cefuroxime, trimethoprim-sulfamethoxazole, and levofloxacin), the increases were statistically significant (P < 0.05). Resistance to the fluoroquinolone remained low in both years (0.1 and 0.6%, respectively); in contrast, resistance to macrolides was consistently greater than 20%, and resistance to trimethoprim-sulfamethoxazole increased from 13.3 to 27.3%. Multidrug resistance, concurrent resistance to three or more antimicrobials of different chemical classes, also increased significantly between years, from 5.9 to 11%. The most prevalent phenotype was resistance to penicillin, azithromycin (representative macrolide), and trimethoprim-sulfamethoxazole. Multidrug-resistant phenotypes that included fluoroquinolone resistance were uncommon; however, two phenotypes that included fluoroquinolone resistance not found in 1997–1998 were encountered in 1998–1999. This longitudinal surveillance study of resistance inS. pneumoniae revealed that significant changes do occur in just a single year and supports the need for surveillance at least on an annual basis, if not continuously.

Download Full-text

1582. Delafloxacin Activity Against Drug-Resistant Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, and Moraxella catarrhalis from US Medical Centers (2014–2018)

Open Forum Infectious Diseases ◽

10.1093/ofid/ofz360.1446 ◽

2019 ◽

Vol 6 (Supplement_2) ◽

pp. S577-S578

Author(s):

Dee Shortridge ◽

Jennifer M Streit ◽

Michael D Huband ◽

Robert K Flamm

Keyword(s):

Streptococcus Pneumoniae ◽

Haemophilus Influenzae ◽

Moraxella Catarrhalis ◽

Active Agent ◽

The United States ◽

Multidrug Resistant ◽

In Vitro Susceptibility ◽

Amoxicillin Clavulanate ◽

Tract Infections

Abstract Background Delafloxacin (DLX) is an anionic fluoroquinolone (FQ) antimicrobial that was approved in 2017 by the United States (US) Food and Drug Administration for the treatment of acute bacterial skin and skin structure infections. DLX recently successfully completed a clinical trial for the treatment of community-acquired bacterial pneumonia (CABP). In the present study, in vitro susceptibility (S) results for DLX and comparator agents were determined for CABP pathogens including Streptococcus pneumoniae (SPN), Haemophilus influenzae (HI), H. parainfluenzae (HP) and Moraxella catarrhalis (MC) clinical isolates from US hospitals participating in the SENTRY Program during 2014–2018. Methods A total of 1,975 SPN, 1,128 HI, 684 MC, and 43 HP isolates were collected from community-acquired respiratory tract infections (CARTI) during 2014–2018 from US hospitals. Sites included only 1 isolate/patient/infection episode. Isolate identifications were confirmed at JMI Laboratories. Susceptibility testing was performed according to CLSI broth microdilution methodology, and CLSI (2019) breakpoints were applied where applicable. Other antimicrobials tested included levofloxacin (LEV) and moxifloxacin (MOX; not tested in 2015). Multidrug-resistant (MDR) SPN isolates were categorized as being nonsusceptible (NS) to amoxicillin-clavulanate, erythromycin, and tetracycline; other SPN phenotypes were LEV-NS or penicillin (PEN)-NS. β-Lactamase (BL) presence was determined for HI, HP, and MC. Results The activities of the 3 FQs are shown in the table. The most active agent against SPN was DLX, with the lowest MIC50/90 values of 0.015/0.03 mg/L. DLX activities were similar when tested against the MDR or PEN-NS for SPN phenotypes. LEV-NS isolates had DLX MIC50/90 results of 0.12/0.25 mg/L. DLX was the most active FQ against HI, HP, and MC. BL presence did not affect FQ MIC values for HI or MC; only 2 HP isolates were BL-positive. Conclusion DLX demonstrated potent in vitro antibacterial activity against SPN, HI, HP, and MC. DLX was active against MDR SPN that were NS to the agents commonly used as treatments for CABP. DLX had excellent activity against LEV-NS SPN. These data support the continued study of DLX as a potential treatment for CABP. Disclosures All authors: No reported disclosures.

Download Full-text